All In Biotech

Free tool

FAERS Monitor: Tobradex

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050616 or its brand name (Tobradex, Dexamethasone, Tobramycin). Reports on generic versions are filed under their own applications.

Reports

3,324

Serious

2,271

68% of reports

Hospitalization

875

Death reported

150

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye pain243
  • off label use226
  • drug ineffective184
  • vision blurred182
  • headache179
  • ocular hyperaemia170
  • eye irritation169
  • nausea168
  • fatigue165
  • dizziness143
  • pain137
  • diarrhoea135
  • visual impairment122
  • dyspnoea121
  • anxiety106

Reports by year received

View as table
YearReports
20048
200523
200644
200730
200841
200959
201058
201177
201293
201374
201495
2015147
2016201
2017168
2018321
2019268
2020258
2021254
2022241
2023238
2024236
2025200
2026190

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,835 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eye painSignal24327.424.26,137
ocular hyperaemiaSignal17022.719.63,508
eye irritationSignal16918.616.12,801
vision blurredSignal1828.47.31,185
visual impairmentSignal1226.25.2534
anxietySignal1062.42.083
dizziness1431.81.553
headache1791.81.666
off label use2261.61.457
pain1371.41.216
dyspnoea1211.41.111
nausea1681.31.215
fatigue1651.31.215
diarrhoea1351.31.111
drug ineffective1840.90.83

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.